



8/14/02

#7
ReceiptExpress Mail No.: EL 500 575 578 US
FILE COPY**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Application of: Roemer *et al.*

Serial No.: 10/032,585

Group Art Unit: 1636

Filed: December 20, 2001

Examiner: Not Yet Assigned

For: GENE DISRUPTION METHODOLOGIES FOR Attorney Docket No.: 10182-016-999
DRUG TARGET DISCOVERY**RECEIVED**

AUG 22 2002

TECH CENTER 1600/2900

REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Filing Receipt Corrections
P.O. Box 2327
Arlington, VA 22202

Sir:

Enclosed is a copy of the updated Filing Receipt mailed on July 10, 2002, by the Patent and Trademark Office in connection with the above-captioned nonprovisional patent application. Applicants note that the Filing Receipt contains an error. The name of Assignee under the heading "Assignment For Published Patent Application" is incorrectly stated on the Filing Receipt as "Pharmaceuticals, Inc." Accordingly, Applicants request that a corrected Filing Receipt be issued in which the Assignee's name is correctly stated as "Elitra Pharmaceuticals, Inc."

Since this error was on the part of the Patent and Trademark Office, Applicants believe that no fee is due. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP deposit account no. 16-1150. A duplicate of this sheet is enclosed.

Respectfully submitted,

*Laura A. Coluzzi Reg No. 30742*BY: *Michael J. Ryan Reg No 41283* 30,742
Laura A. Coluzzi (Reg. No.)Date: August 12, 2002

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, NY 10036-2711
(212) 790-9090

Enclosure




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/032,585 /	12/20/2001 /	1636 /	2540	10182-016-999	7	77	29

20583
PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711



CONFIRMATION NO. 8340 ✓
UPDATED FILING RECEIPT

OC000000008429028

Date Mailed: 07/10/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Terry Roemer, Montreal, CANADA;
Bo Jiang, Montreal, CANADA;
Charles Boone, Toronto, CANADA;
Howard Bussey, Westmount, CANADA;
Kari L. Ohlsen, San Diego, CA;

RECEIVED
AUG 22 2002
TECH CENTER 1600/2900

Assignment For Published Patent Application

ELITRA Pharmaceuticals, Inc.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/792,024 02/20/2001 /
AND CLAIMS BENEFIT OF 60/259,128 12/29/2000
AND CLAIMS BENEFIT OF 60/314,050 08/22/2001


Foreign Applications

If Required, Foreign Filing License Granted 02/27/2002

Projected Publication Date: 10/17/2002

Non-Publication Request: No

Early Publication Request: No



**** SMALL ENTITY ****

Title

Gene disruption methodologies for drug target discovery

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).